A family are fundraising to help support their toddler who has been diagnosed with a rare genetic disorder that affects her ...

"Cancer cells from patient's primary tumours that ended up relapsing in the liver or the lung early on adopt cellular states ...

Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care ...

SELLAS’s Phase 2 clinical trial for its investigational drug SLS009 for acute myeloid leukemia showed positive results.

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response ...

BGB-16673 showed high overall response rates in relapsed/refractory CLL/SLL, with a notable 94.4% response at the 200-mg dose level. Safety analysis revealed that 95.6% of patients experienced ...

Aptevo Therapeutics (APVO) presented preliminary results from its ongoing Phase 1b/2 RAINIER study evaluating mipletamig, a CD123 x CD3 bispecific ...

Introduction Asthma is a chronic respiratory disorder requiring ongoing medical management. This ecological study ...

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of ...